Fulcrum Therapeutics (FULC) Accumulated Depreciation (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Accumulated Depreciation data on file, last reported at $15.2 million in Q1 2026.

• Accumulated Depreciation for Q1 2026 came in at $15.2 million, up 4.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.2 million (up 4.21% YoY), and the FY2025 annual result was $15.6 million, up 9.75% from the prior year.
• Accumulated Depreciation slipped to $15.2 million in Q1 2026 per FULC's latest filing, from $15.6 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $15.6 million in Q4 2025 and troughed at $8.8 million in Q1 2022.
• A 5-year average of $12.8 million and a median of $13.2 million in 2024 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2022 and 2026: Accumulated Depreciation jumped 31.19% in 2022, then grew 4.21% in 2026.
• A 5-year view of Accumulated Depreciation shows it stood at $10.7 million in 2022, then advanced by 19.68% to $12.8 million in 2023, then rose by 11.73% to $14.3 million in 2024, then advanced by 9.75% to $15.6 million in 2025, then decreased by 2.7% to $15.2 million in 2026.
• Business Quant data shows FULC's Accumulated Depreciation at $15.2 million in Q1 2026, $15.6 million in Q4 2025, and $15.3 million in Q3 2025.